UBS’s Pacific Biosciences PACB Stock Holding History

UBS’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q1	–	Sell	-500	Closed	-$3K	–	10684
2013 Q4	$3K	Sell	500 -1,300	-72%	-$5.97K	﹤0.01%	9871
2013 Q3	$10K	Buy	+1,800	New	+$6.25K	﹤0.01%	8818

Other funds holding PACB

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

OIM

Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return

BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return

Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

RCM

Raging Capital Management Rocky Hill, New Jersey $18.2M AUM 17.75% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS's PACB Position: Q3 2014 in Review

UBS increased its Pacific Biosciences (PACB) stake by 145% in Q3 2014, buying an estimated $17.5K and bringing the position to 5,643 shares worth $27K. The position accounts for ﹤0.01% of the portfolio, ranked #7621.

UBS first reported a position in PACB in Q2 2013 and has held it in 6 quarters since. 88 funds tracked by Wall St. Rank hold PACB as of Q3 2014.

UBS held 5,643 shares of Pacific Biosciences worth $27K as of Q3 2014.
UBS bought 3,343 Pacific Biosciences shares in Q3 2014, an estimated $17.5K.
Pacific Biosciences made up ﹤0.01% of UBS's portfolio in Q3 2014, its #7621 holding.
UBS first reported a position in Pacific Biosciences in Q2 2013 and has held it in 6 quarters since.
88 funds tracked by Wall St. Rank held Pacific Biosciences as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.